Navigation Links
Estrogen-lowering drugs minimize surgery in breast cancer patients
Date:5/20/2010

A nationwide study has confirmed the benefit of giving estrogen-lowering drugs before surgery to breast cancer patients. The treatment increased the likelihood that women could undergo breast-conservation surgery, also called lumpectomy, instead of mastectomy.

The study's chair, Matthew J. Ellis, MD, PhD, the Anheuser-Busch Endowed Chair in Medical Oncology and a breast cancer specialist with the Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, will present the findings June 7 at the annual meeting of the American Society of Clinical Oncology.

Sponsored by the American College of Surgeons Oncology Group, the study took place at 118 hospitals across the country and involved 352 postmenopausal women with estrogen-receptor positive (ER+) breast tumors. The participants received aromatase inhibitors for 16 weeks before surgery for breast cancer, and the extent of their tumors was monitored before and after the drug treatment.

The lead investigator at the Washington University site was Julie A. Margenthaler, MD, assistant professor of surgery and a breast surgeon at the Siteman Cancer Center.

Aromatase inhibitors are also referred to as estrogen-lowering agents because they interfere with the body's production of estrogen, a hormone that stimulates the growth of ER+ breast tumors. ER+ is the most common breast cancer, accounting for three-quarters of cases.

All women in the study had stage II or III breast cancer, in which tumors are about an inch or larger in size and may have spread to the lymph nodes in the underarm area. Participants were placed in one of three groups at the study's start:

  • marginal, meaning breast-conservation surgery was possible but likely to be disfiguring or to require several surgical procedures;
  • mastectomy-only, meaning breast-conservation surgery was not possible; and
  • inoperable, meaning mastectomy would not completely remove the cancer.

After the 16-week aromatase inhibitor therapy, the women were reevaluated to see which surgical option was appropriate for them. The results showed that 82 percent of women in the marginal group, 51 percent in the mastectomy-only group and 75 percent in the inoperable group had successful breast-conservation surgery instead of mastectomy.

"Aromatase inhibitor therapy shrank the tumors in many of these women and improved surgical outcomes," Ellis says. "These results will encourage a change in practice across the country so that more women can benefit from the currently underutilized approach of administering estrogen-lowering agents before surgery."

The study participants were randomly assigned to receive one of three estrogen-lowering agents: exemestane (25 mg daily), letrozole (2.5 mg daily) or anastrozole (1 mg daily). No statistically significant difference in effectiveness was found among the three drugs.

Ellis explains that there are other benefits to using estrogen-lowering agents before surgery.

"ER+ breast cancer can be thought of as a chronic disease because patients generally take estrogen-lowering agents for many years after surgery to repress recurrence," Ellis says. "In other chronic diseases, such as hypertension or diabetes, a patient's response to treatment is continually monitored. But we've never done that with breast cancer. By treating breast cancer patients with estrogen-lowering drugs for three or four months before surgery, we can monitor treatment response and then specifically tailor surgical and post-surgical treatment based on this response."


'/>"/>

Contact: Gwen Ericson
ericsong@wustl.edu
314-286-0141
Washington University in St. Louis
Source:Eurekalert  

Related medicine news :

1. Long-term use of anti-anxiety drugs continues in B.C. despite known health risks: UBC study
2. IVF, Fertility Drugs Might Boost Autism Risk
3. System that predicts protein structures could help researchers design drugs
4. Euthanasia and the use of end-of-life drugs without explicit request
5. U.S. FDA Adds 25 New Firms to Import Alert for Promotion of Unapproved New Drugs According to FDAImports.com, LLC
6. Pharmaceutical companies provide EPA 100 drugs to help predict toxicity
7. Bone Drugs Not Linked to Rare Fractures
8. Impotence Drugs May Aid Brain Tumor Treatment
9. Monitoring and control can limit side effects of promising cancer drugs
10. Parkinsons Drugs Tied to Compulsive Behaviors
11. Stomach Acid Drugs Come with Dangers, Studies Show
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Estrogen-lowering drugs minimize surgery in breast cancer patients
(Date:5/6/2016)... ... May 06, 2016 , ... Kenneth Cochran, DSc, RN, FACHE, ... of the South announced today that Dr. Robert Menuet, Interventional Cardiologist with Cardiovascular ... Ultrasound Guided Coronary Atherectomy. , This procedure involves the removal of ...
(Date:5/5/2016)... ... May 05, 2016 , ... TransWipe Volume 3 is ... X. Drag and drop a TransWipe preset between two video clips to instantly add ... wipes to colored panels with customizable color and orientation options. TransWipe Volume 3 is ...
(Date:5/5/2016)... ... 2016 , ... Qrono Inc. , a specialty pharmaceutical ... with the Australian critical medicine company, Phebra Pty Ltd. , to develop ... can offer improved therapeutic benefits over oral formulations, including better bioavailability, improved adherence, ...
(Date:5/5/2016)... ... May 05, 2016 , ... Einstein Medical is proud ... cover the latest news and commentary at the 2016 ASCRS/ASOA Symposium and Congress, which ... American Society of Cataract and Refractive Surgery and the American Society of Ophthalmic Administrations ...
(Date:5/5/2016)... ... ... weekend, from Friday, May 6 - Sunday, May 8, fifteen elite athletes from Team ... Fi Mountain Bike Camp, hosted in conjunction with WTB and Cannondale ... Moeschler, who’ll share pro tips with the injured veterans as they rip down some of ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... ALBANY, New York , May 4, 2016 /PRNewswire/ ... published by Transparency Market Research entitled "Brain Computer Interface Market ... Forecast 2016 - 2024," the  global brain computer interface (BCI) ... bn by 2024. The market is estimated to expand ... period from 2016 to 2024. A BCI ...
(Date:5/4/2016)... -- Yissum Research Development Company of ... it had signed an exclusive world-wide licensing and research ... protein degradation and immunomodulatory drugs for cancer and immune ... representing first-in-class therapy for hematologic and solid malignancies. Financial ... The novel technology was developed by Yinon Ben-Neriah ...
(Date:5/4/2016)... , May 4, 2016 ... of the  "Global Acute Ischemic Stroke Market ... to their offering.       (Logo: ... Global Acute Ischemic Stroke Market and Competitive ... Acute Ischemic Stroke pipeline products, Acute Ischemic ...
Breaking Medicine Technology: